Related Experiment Video

Updated: Jun 28, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Correction to 'Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years'

    Journal of the European Academy of Dermatology and Venereology : JEADV
    |June 27, 2026
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
    09:32

    Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

    Published on: September 26, 2019

    Related Experiment Videos

    Last Updated: Jun 28, 2026

    Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
    08:36

    Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

    Published on: April 7, 2023

    Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
    09:32

    Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

    Published on: September 26, 2019

    Related Concept Videos

    Pharmacovigilance01:19

    Pharmacovigilance

    Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
    This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
    In some cases, there...
    Clinical Trials: Overview01:11

    Clinical Trials: Overview

    Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

    Articles linked to this work by shared authors, journal, and citation graph.

    Female genital lichen sclerosus.

    Journal of the European Academy of Dermatology and Venereology : JEADV·2026

    Experience-based recommendations for the diagnosis and management of early-stage nail unit melanoma.

    Journal of the European Academy of Dermatology and Venereology : JEADV·2026

    Optimizing therapy in hidradenitis suppurativa: Combination, sequencing and treat-to-target.

    Journal of the European Academy of Dermatology and Venereology : JEADV·2026

    The future management of HS: People with HS as partners.

    Journal of the European Academy of Dermatology and Venereology : JEADV·2026

    Targeted therapies in pemphigus vulgaris: Emerging horizons beyond rituximab.

    Journal of the European Academy of Dermatology and Venereology : JEADV·2026

    Upcoming novel treatments for hidradenitis suppurativa: An overview of the pipeline.

    Journal of the European Academy of Dermatology and Venereology : JEADV·2026

    Values-Based Leadership in Modern Medicine: Lessons From the Naval Submarine Force.

    Cureus·2026

    Brief Report: Reassessment of bTMB as a Predictive Biomarker in NSCLC Immunotherapy-A Reanalysis of OAK and POPLAR.

    JTO clinical and research reports·2026

    Toxicological Vulnerabilities and Emerging Safety Signals in Modified mRNA Vaccine Technology: A Narrative Review of the COVID-19 Experience.

    Journal of toxicology·2026

    Comparative efficacy of non-pharmacological interventions for amnestic mild cognitive impairment: a network meta-analysis.

    Frontiers in aging neuroscience·2026

    A candidate gonococcal outer membrane vesicle vaccine which induces persistent immunity in three genetically distinct species of mouse and is similarly immunogenic when formulated with and without aluminium adjuvant.

    Frontiers in immunology·2026

    Efficacy and safety of nafamostat mesilate for anticoagulation during ECMO/CRRT: insight from the integrated meta-analysis and FAERS pharmacovigilance study.

    Frontiers in pharmacology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us